Shanghai Pharmaceuticals Holding Co Ltd
XBER:S1R
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Shanghai Pharmaceuticals Holding Co Ltd
XBER:S1R
|
CN |
|
G
|
GATX Corp
F:GAX
|
US |
|
M
|
Masimo Corp
SWB:3M4
|
US |
|
Y
|
Yum China Holdings Inc
XETRA:0YU
|
CN |
|
China Lilang Ltd
HKEX:1234
|
CN |
|
M
|
Merck & Co Inc
SGO:MRK
|
US |
|
Paysign Inc
NASDAQ:PAYS
|
US |
|
G
|
GATX Corp
SWB:GAX
|
US |
|
N
|
Natwest Group PLC
XBER:RYS1
|
UK |
|
D
|
Diageo PLC
OTC:DGEAF
|
UK |
Wall St Price Targets
S1R Price Targets Summary
Shanghai Pharmaceuticals Holding Co Ltd
According to Wall Street analysts, the average 1-year price target for S1R is 1.56 EUR with a low forecast of 0.94 EUR and a high forecast of 2.02 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is S1R's stock price target?
Price Target
1.56
EUR
According to Wall Street analysts, the average 1-year price target for S1R is 1.56 EUR with a low forecast of 0.94 EUR and a high forecast of 2.02 EUR.
What is the Revenue forecast for Shanghai Pharmaceuticals Holding Co Ltd?
Projected CAGR
7%
Over the last 14 years, the compound annual growth rate for Revenue has been 12%. The projected CAGR for the next 3 years is 7%.
What is the Operating Income forecast for Shanghai Pharmaceuticals Holding Co Ltd?
Projected CAGR
8%
Over the last 14 years, the compound annual growth rate for Operating Income has been 10%. The projected CAGR for the next 3 years is 8%.
What is the Net Income forecast for Shanghai Pharmaceuticals Holding Co Ltd?
Projected CAGR
5%
Over the last 14 years, the compound annual growth rate for Net Income has been 8%. The projected CAGR for the next 3 years is 5%.
